Immix Biopharma
clinical trial and supply agreement with for anti immix | Immix Biopharma
Company
Deck Type
Sector
Industry
Deck date
December 2023
Slide
48 of 62
Similar slides by Immix Biopharma
See diffirences between slides (animation)
Investor Presentation
March 2024
clinical trial and supply agreement with for anti immix fro | Immix Biopharma
Investor Presentation
January 2024
clinical trial and supply agreement with for anti immix | Immix Biopharma
Investor Presentation
November 2023
clinical trial and supply agreement with for anti immix | Immix Biopharma
Investor Presentation
November 2023
clinical trial and supply agreement with for anti immix | Immix Biopharma
Related slides by other companies
RenovoRx
IPO
August 2021
locally advanced pancreatic cancer and | RenovoRx
RayzeBio
IPO
September 2023
phase trial in first line combination treatment of | RayzeBio
Alkermes
Investor Day
March 2021
enhanced the anti tumor efficacy of in mouse tumors tumor growth inhibition overall survival combination with growth factor pathway inhibitors days vehicle complete responses days in combination with either or not shown resulted in enhanced tumor suppression and survival relative to groups similar results observed with a mouse surrogate of which is a selective inhibitor of the angiogenesis factor alkermes internal data on file the mouse of was used in mouse tumor model | Alkermes
AstraZeneca
Results
November 2024
top i lung cancer | AstraZeneca
Other recent decks by Immix Biopharma
See all presentations (11 decks)
Investor Presentation
March 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights